Bullish flow in Pfizer (PFE), with shares up $1.51, or 6.35%, near $25.36. Options volume extremely heavy with 1.04m contracts traded and calls leading puts for a put/call ratio of 0.2, compared to a ...

Pfizer's COVID-19 products continue to generate significant cash flow that helps bolster the company's dividend. The big drugmaker has opportunities to monetize assets to raise additional cash. Pfizer ...

Pfizer can cover its dividends with free cash flow, but doesn't have a huge cushion. The company faces some risks from pipeline setbacks, patent expirations, and U.S. government policies. Its dividend ...

A new gel-based treatment could change the way diabetic wounds heal. By combining tiny healing messengers called vesicles with a special hydrogel, scientists have created a dressing that restores ...

Pfizer's 2.4% dividend increase has sparked mixed reactions, but income-focused investors appreciate the stability and resilience, especially with a current yield of 6.6%. Despite concerns about debt ...

Pfizer Inc. (NYSE:PFE) is one of the Best Dividend Leaders to Buy Now. The company’s strategy focuses on steadily increasing its dividend, reinvesting in the business with strong financial returns, ...